Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Watching for a breakout tomorrow !
$1.50 Close chart is setup for a pop anyday
The shorts are gone, now we need phase three trial dates, trial outcomes, and a buyout offer that makes our eyes bug out... too much to ask for?, nah, I think not.
Patience is the only key to unlock this door.
Could see some halts on the way up next few trading trades if we get volume
$1.50s float is tiny
Look good volume picking up
Picked some 1.50's
they turned up nicely, lets see if the share price follows, although I am waiting for a more material event to happen with this company, which I fully expect to happen tomorrow or before the end of the year
https://stockcharts.com/h-sc/ui?s=wint&p=D&yr=0&mn=6&dy=0&id=p38090673899
https://www.barchart.com/stocks/quotes/wint/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100
https://www.barchart.com/stocks/quotes/wint/opinion
https://finance.yahoo.com/quote/wint/
Not sure about this one just yet, could see more downside before anything new, waiting for sub $1.20 to place a bet, then 6 months of not knowing
Yes, it started moving up the day of that PR. Hopefully, there will be some news that comes out of the conference. $WINT
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
This must be the reason for uptrend this week, it should move up into the 06/14/2023 event:
https://finance.yahoo.com/news/windtree-therapeutics-host-virtual-r-120000853.html
Looking much better today! Can we break $2 today? $WINT
https://stockcharts.com/h-sc/ui?s=wint&p=D&yr=0&mn=6&dy=0&id=p38090673899
https://www.barchart.com/stocks/quotes/wint/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100
https://www.barchart.com/stocks/quotes/wint/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100
https://www.barchart.com/stocks/quotes/wint/opinion
https://finance.yahoo.com/quote/wint/
As of May 15, 2023, there were 5,147,919 shares of the registrant’s common stock outstanding, par value $0.001 per share.
Market Cap 1,354,429 05/19/2023
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC boosted its position in Windtree Therapeutics by 559.5% during the 3rd quarter. Virtu Financial LLC now owns 100,808 shares of the company’s stock worth $30,000 after acquiring an additional 85,522 shares during the period. Envestnet Asset Management Inc. boosted its position in Windtree Therapeutics by 894.7% during the third quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock worth $32,000 after purchasing an additional 96,515 shares during the period. Millennium Management LLC boosted its position in Windtree Therapeutics by 411.1% during the second quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after purchasing an additional 64,232 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Windtree Therapeutics by 54.1% during the second quarter. Renaissance Technologies LLC now owns 361,395 shares of the company’s stock worth $151,000 after purchasing an additional 126,949 shares during the period. Institutional investors own 4.37% of the company’s stock.
Large open gap to fill to the upside near $6
https://www.nasdaq.com/market-activity/spos
$2.93 SPO
After getting decimated after the $2.93 offering, it looks like insiders have been buying. A form 4 yesterday and today. Very low float here, even with the offering. $1.60's seems way overdone. $WINT
https://stockcharts.com/h-sc/ui?s=wint&p=D&yr=0&mn=6&dy=0&id=p38090673899
https://www.barchart.com/stocks/quotes/wint/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100
https://www.barchart.com/stocks/quotes/wint/opinion
What is the future from here? Any upcoming revenues expected?
Maybe sub $2 today
How low can it go. It is already trading below the offer price. Just insane
Pardon me Tuesday…. Even drove it up to 18 bucks Monday
Unbelievable these algo’s big dogs cashing in
They were filling 10k blocks above 10 bucks yesterday
Don’t mess with these robots
Lost all my money in this. Hope are faded when seeing waterfall in last two sessions.
Amazing algo’s triggered this to $18 two days ago
With volume being consistent and above the actual number of shares who would be manipulating this? The stick is worth 100 million$ at least with the recent patent and pipeline of products they have.
Why you are Bullish on the Garbage?
With this low float is it still worth it to buy?
Heaven for shorters
WTH im eating crow with my garbage comment, Dam had a limit set at 6.75 but able to turn a small slice at 16.65
WINT: Likely hit over 700% up sometime today. (Goodbye "garbage" theory.)
WINT: However, looks like they just made a 'POWER PLANT' out of this RE-Cycled GARBAGE???
WINT $11 WINTW .01
like a steaming pile of garbage
now its @ approximately 12.5 presplit. And being pushed down!
So were looking at 8.25
I hate RS WINT wasn't moving at .16 except for spike to .38 and it won't at $50 it will move lower until their drugs are approved
Came out this morning at 10 am: Windtree Therapeutics Inc.'s board of directors has approved a 1-for-50 reverse stock split of the company's issued and outstanding stock.
On Friday, the reverse split will become effective at 12:01 a.m. ET and shares will open for trading on a split- adjusted basis, the Warrington, Pa. -based cardiovascular disorder-focused biotechnology company said Thursday.
Windtree expects the reverse stock split to increase the market price per share of the stock, bringing the company into compliance with Nasdaq's listing requirements.
The reverse stock split will reduce the number of shares of outstanding stock to about 900,000 shares from about 44.5 million shares, Windtree said.
WHERE DID YOU GET THAT. PIPELINE WILL GROW ORGANICALLY.
WINT: Hey, Bro, see below what my 'Lady Friend' here in San Diego has to say on THAT note!! (LIVE, here on "Mission Beach"!!)
"Hey, iHub Homeboys!! Let's Short-SQUEEZE the duck out of WINT shares today!!"
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
Followers
|
105
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
3267
|
Created
|
08/13/05
|
Type
|
Free
|
Moderators |
Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant therapies to treat respiratory disorders and diseases based on its KL4 surfactant and capillary aerosol-generating technologies. Its development stage products include Surfaxin, a synthetic, peptide-containing surfactant in phase III clinical trial for the prevention of respiratory distress syndrome in premature infants; Surfaxin LS, a Phase III trial product to improve ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant that has completed first pilot Phase II clinical trial for the treatment of respiratory distress syndrome in premature infants.
The company has a license agreement with Philip Morris USA Inc. to use its capillary aerosolization technology for use with pulmonary surfactants for the respiratory diseases and conditions; and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain.
Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
• | Surfaxin® (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants: The Company is conducting a comprehensive preclinical program to validate its optimized biological activity test (BAT), a key remaining issue that must be addressed to potentially gain U.S. Food and Drug Administration (FDA) marketing approval for Surfaxin in the United States. The Company has had several interactions with the FDA intended to ensure that the comprehensive preclinical program would ultimately satisfy the FDA. In January 2011, the Company announced that the FDA had provided guidance to increase the sample size of a specific data set by testing additional Surfaxin batches. To comply with the FDA's suggestion, the Company has successfully manufactured eight Surfaxin batches and presently plans to manufacture two additional Surfaxin batches for use in the comprehensive preclinical program. The Company presently plans to complete all related analytical testing and concordance studies, and be in a position to file a Surfaxin Complete Response in the third quarter of 2011. |
• | Surfaxin LSTM (lyophilized lucinactant) for neonatal RDS : The Company continues to advance this program. Its plans for 2011 include establishing a commercial-scale manufacturing capability at a cGMP-compliant contract manufacturer with expertise in lyophilized formulations and seeking regulatory guidance from the FDA and the European Medicines Agency (EMA) for the planned clinical development program. |
• | Aerosolization Technology : Recently, at the 2011 Pediatric Academic Societies Annual Meeting (PAS), new data was presented including: (i) a collaborative study indicating that aerosolized KL4 surfactant significantly improved lung function and survival when treating Acute Lung Injury in a well established preclinical model of this severe respiratory condition, (ii) a dose-ranging assessment of aerosolized KL4 surfactant in a widely recognized preclinical model of RDS, demonstrating significant improvement in lung function, lung structural integrity and pulmonary inflammatory mediator profile following treatment with aerosolized KL4 surfactant versus controls, and (iii) a study highlighting the Company's novel patient interface technology intended to increase the efficiency of pulmonary aerosol drug delivery to patients requiring positive pressure ventilatory support. |
| Regarding the Company's lead aerosolized KL4 surfactant program, Aerosurf® (aerosolized lucinactant for neonatal RDS), data from the preclinical dose ranging assessment study presented at PAS mentioned above suggests that, out of several doses tested, KL4 surfactant delivered via the Company's proprietary capillary aerosol generator during a 20 to 30 minute dosing interval results in the most favorable physiologic outcomes. This study provides guidance for future clinical dosing strategies for this program. The Company's plans for 2011 include finalizing the clinical and potential commercial design of the capillary aerosol generator, finalizing the clinical and potential commercial design for the novel patient interface, and seeking regulatory guidance in the U.S. and Europe for the planned development program. |
Investor Relations Contacts
2010-11 Press Releases
May 13, 2011 10-Q http://ih.advfn.com/p.php?pid=nmona&article=47677338
May 13, 2011 http://ih.advfn.com/p.php?pid=nmona&article=47666790 A Brighter Decade Ahead for Biotech - Equity Research on Discovery Laboratories and Mylan Inc
May 11, 2011 8k http://ih.advfn.com/p.php?pid=nmona&article=47626029
May 19, 2010
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval
May 14, 2010
Discovery Labs' Phase 2a Aerosurf® Study Published in Journal of Aerosol Medicine and Pulmonary Drug Delivery
April 27, 2010
Discovery Labs Provides Updates on Surfaxin®, Other Key Programs and First Quarter 2010 Financial Results
March 10, 2010
Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update
February 23, 2010
Discovery Labs Announces Completion of $16.5 Million Public Offering
February 18, 2010
Discovery Labs Prices $16.5 Million Public Offering of Common Stock and Warrants
February 17, 2010
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants
February 16, 2010
Discovery Labs Receives FDA Guidance Regarding Pathway to Potential SURFAXIN® Approval
January 19, 2010
POPG, a Key Component of Discovery Labs KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach
Management Team View Bio
W. Thomas Amick, Interim CEO
Russell Clayton, D.O.
Vice President, Academic and Medical Affairs, Acting Head, Regulatory Affairs and Preclinical Research
Kathryn Cole
Senior Vice President, Human Resources
John G. Cooper
Executive Vice President, Chief Financial Officer
David L. Lopez, C.P.A., Esq.
Executive Vice President, General Counsel
Charles F. Katzer
Senior Vice President, Manufacturing Operations
Thomas F. Miller, Ph.D., MBA
Senior Vice President, Commercialization & Corporate Development
Gerald J. Orehostky
Senior Vice President, Quality Operations
Robert Segal, M.D., F.A.C.P.
Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer
Mary B. Templeton, Esq.
Senior Vice President, Deputy General Counsel
Do your own DD & trade smart
(DSCO) Pre-Market Trading (DSCO) After Hours Trading
(DSCO) Short
Technical Indicators (Barchart)
Yahoo! Finance (i.e Real-Time)
Last update: June 03,2010
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |